Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
Blood Advances(2024)
关键词
non-Hodgkin lymphoma,peripheral T-cell lymphoma,cutaneous T-cell lymphoma,nivolumab,brentuximab vedotin
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要